^
    CANCER:

    Spindle Cell Sarcoma





    Show legend
    Group by Gene:
    Include preclinical:

    0
    Progesterone receptor agonist
    megestrol
    pazopanib
    		1
    Multi-tyrosine kinase inhibitor
    regorafenib
    cabozantinib tablet
    anlotinib
    2
    PD1 inhibitor
    pembrolizumab
    camrelizumab
    3
    Alkylating agent, DNA inhibitor
    trabectedin
    4
    TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
    larotrectinib
    5
    Aromatase inhibitor
    Aromatase inhibitor
    anastrozole
    6
    BMI1 inhibitor
    BMIi-1
    crizotinib
    		7
    ALK inhibitor
    alectinib
    ceritinib
    8
    PARP inhibitor
    PARP inhibitor
    olaparib
    9
    mTOR inhibitor
    temsirolimus
    everolimus
    10
    mTORC1 inhibitor, mTORC2 inhibitor
    CB-228
    11
    PD-L1 inhibitor, PARP inhibitor
    avelumab + talazoparib
    12
    TCR modulator, NY ESO 1 inhibitor
    TBI-1301
    13
    AKT inhibitor
    capivasertib
    14
    EZH2 inhibitor
    tazemetostat
    15
    Glutaminase inhibitor
    IPN60090
    16
    BRAF inhibitor, BRAF V600E inhibitor
    vemurafenib
    17
    PRMT5 inhibitor
    MRTX1719
    18
    MEK inhibitor
    trametinib
    19
    CD70-targeted antibody-drug conjugate
    JNJ-0631
    20
    PD1 inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab
    21
    TCR modulator, MAGE-A4 inhibitor
    ADP-A2M4
    22
    DNA synthesis inhibitor, PARP inhibitor
    olaparib + temozolomide
    23
    c-MET inhibitor, MEK inhibitor
    MEK inhibitor + c-MET inhibitor
    24
    Chemotherapy
    VAC
    25
    β-catenin inhibitor, CBP inhibitor, Microtubule inhibitor
    eribulin mesylate
    26
    PDGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor
    imatinib
    27
    Topoisomerase II inhibitor, DNA synthesis inhibitor
    doxorubicin hydrochloride + dacarbazine
    28
    TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor inhibitor, ALK inhibitor, JAK2 inhibitor, TNK2 inhibitor
    entrectinib
    29
    ROS1 inhibitor, ALK inhibitor
    lorlatinib
    30
    PD1 inhibitor, GM-CSF agonist
    nivolumab + talimogene laherparepvec
    31
    pan-RAF inhibitor, VEGF-A inhibitor, mTOR inhibitor, Multi-tyrosine kinase inhibitor
    bevacizumab + sorafenib + temsirolimus
    32
    pan-RAF inhibitor, Src kinase inhibitor
    BAL3833
    33
    PLK4 inhibitor
    CFI-400945
    34
    MCSP inhibitor
    CSPG4.TNK
    35
    CD30-targeted antibody-drug conjugate, ALK inhibitor, Microtubule inhibitor
    ceritinib + brentuximab vedotin
    crizotinib + brentuximab vedotin
    36
    Glutamine antagonist, Nerve growth factor inhibitor
    DR6MP + JHU395
    37
    Nerve growth factor inhibitor
    DR6MP
    38
    β-catenin inhibitor, XPO1 inhibitor, CBP inhibitor, Microtubule inhibitor
    eribulin mesylate + selinexor
    39
    WEE1 inhibitor
    AZD1775
    40
    ATR inhibitor
    BAY 1895344
    41
    Bifunctional alkylating agent, Topoisomerase II inhibitor, DNA synthesis inhibitor
    cisplatin + ifosfamide + epirubicin
    42
    Topoisomerase II inhibitor, Tubulin polymerization inhibitor, RNA synthesis inhibitor
    vincristine + dactinomycin
    43
    Bifunctional alkylating agent, Topoisomerase II inhibitor
    doxorubicin hydrochloride + ifosfamide
    44
    DNA synthesis inhibitor
    dacarbazine
    45
    DNA synthesis inhibitor, Topoisomerase I inhibitor
    temozolomide + irinotecan
    46
    CD122 agonist, IL-2 stimulant
    NKTR-214
    No biomarker
    PGR positive
    ER positive
    FN1-ALK fusion
    NTRK3 fusion
    ER positive + PGR positive
    HR positive
    NTRK1 fusion
    BRAF V600E
    NTRK2 fusion
    CTAG1B expression
    KRAS G12V
    AKT1 E17K
    SMARCB1 negative
    TP53 mutation
    CD70 expression
    NF2 E108X
    AKT1 mutation + mTOR mutation
    TMB-H
    PALB2 deletion
    RAD51B deletion
    BRCA2 mutation
    BRCA1 mutation
    HLA-A*02:01 + MAGEA4 expression
    HRD
    RBPMS-MET fusion
    TPM3-NTRK1 fusion
    KIAA1549-BRAF fusion + PTEN deletion
    TMB-H + PD-L1 overexpression
    MYH9-ALK + ALK-WDR43
    PTEN mutation + TSC1 mutation
    NF1 mutation
    TFG-ROS1 rearrangement
    YWHAE-JAZF1 fusion
    QKI-RAF1 fusion
    NF1 mutation + CDKN2A deletion + CDKN2B deletion + MTAP deletion
    EML4-NTRK3 rearrangement
    NF1 mutation
    Chr del(2)(p12)
    Chr amplification(20)(p12.2)
    Chr amplification(4)(q26)
    ATRX mutation
    PLK4 expression
    CSPG4 overexpression
    HAT1 overexpression
    RANBP2-ALK rearrangement + TNFRSF8 expression
    TSC2 A736V
    TJP1-ROS1 fusion + NF1 mutation
    Chr del(2)(q14.1)
    Chr amplification(8)(q22.2)
    Chr amplification(8)(q13.2)
    Chr del(1)(q44)
    Chr del(11)(q25)
    Chr del(3)(q14.2)
    Chr amplification(4)(q22.1)
    ALK1 rearrangement
    SQSTM1-NTRK1 fusion
    ETV6-NTRK3 fusion
    MAN1A1-ROS1 rearrangement
    CD8 positive
    Chr amplification(13)(q13.3)